# Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

> **NCT00037596** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** cytarabine.

## Key facts

- **NCT ID:** NCT00037596
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2003-04
- **Final completion:** 2003-04
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00037596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00037596, "Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00037596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*